-
Galloway accuser could not foresee publishing-sector fallout, lawyer argues
-
No. 22 UCLA defeats No. 5 Arizona 84-75 despite Kharchenkov's 38 points
-
New York City Center revives In the Heights as a timely community story
-
Vessel operator seeks witnesses after Vancouver grounding
-
Godzilla Minus Zero shifts focus toward postwar human drama
-
US Air Force deploys F-16 fighters to remote Aleutian base for readiness drill
-
Mehbooba Mufti urges dialogue and renewed Central Asia links for Kashmir
-
Bezos grant helps Seattle nonprofit move thousands of families toward housing
-
Seacliff Healthcare Seeks Specialist GP in Thirroul
-
Shrini Srivastava joins crew of Varanasi-Delhi Vande Bharat Sleeper service
-
US stocks fall before midterm Election Day as technology shares weaken
-
Nearly Half of Australian Workers Overqualified, Survey Finds
-
BLS Polymers makes strong market debut at ₹248 per share
-
RBI eases export-declaration compliance for individual service exporters
-
Petrol and diesel prices remain broadly steady across major Indian cities
-
India proposes more import entry points for drugs and medical devices
-
Reliance shares remain in focus after near-12% surge
-
Derek Tierney Outlines Ten-Year Strategy for National Digital Health System
-
2026 Arizona Midterms: Key Races, Ballot Measures, and Voter Deadlines
-
NBC’s Steve Kornacki Reveals Tech Habits Ahead of Midterm Elections
-
Coal India prepares possible $1 billion Mahanadi Coalfields listing
-
India and Israel oppose UN draft on regional conventional arms control
-
Julia Stiles and Ezra Sosa Share Emotional Farewell After 'DWTS' Elimination
-
BLS Polymers shares open 65.3% above IPO price
-
US Buildings Threatened by Wildfires Could Triple by 2060
-
Capital-markets shares rally as Motilal Oswal and Angel One lead gains
-
Why Pregnancy Cost Estimates Fail: A Family’s $9,000 Surprise
-
Latino Voters Defy ICE Fears, Turn Out in Record Numbers for Midterms
-
US Strikes Iranian Targets in Strait of Hormuz Ahead of Midterms
-
ITC shares rise as analysts anticipate gradual cigarette-business recovery
-
Brodeur’s Overtime Goal Secures Bethlehem’s Second Consecutive Sectional Title
-
Reliance rally puts historical one-year return pattern in focus
-
Rare 1970 Plymouth ‘Cuda 426 Hemi Listed for $400,000
-
Kuwait edges Oman 1-0 in veterans Gulf Cup in Doha
-
The Digital Burden: Why Instant Messaging Feels Like a Full-Time Job
-
Saudi Aramco quarterly profit climbs 34.6% amid elevated oil prices
-
Alberta Tabled Controversial Riding Boundary Maps Amid Gerrymandering Accusations
-
Washington reports movement in Iran negotiations aimed at preventing escalation
-
Hong Kong court set to sentence activist Joshua Wong in security case
-
Korea’s Labor Share of GDP Hits Record Low Amid Semiconductor Boom
-
Australia raises benchmark rate to highest level in 18 years
-
littlefish and Halo Dot Partner to Replace Payment Terminals with SoftPOS
-
'The Remarried Empress' Cast Discusses Bringing Fantasy Royal Drama to Life
-
Kuwait inspectors destroy 115 kilograms of unverified meat in Farwaniya
-
Asian stocks retreat as AI worries outweigh steep oil-price drop
-
Egypt Accelerates Construction of 341km Sinai Railway Linking Arish and Taba
-
Hamad International Airport stages emergency drills during WATAN 2026
-
John Schneider Admits Owes Millions in 'Dukes of Hazzard' Divorce Battle
-
Global failure to punish attacks leaves journalists at continuing risk
-
Philippine Authorities Report Progress in Thomas Markle Sr. Child Pornography Probe
Ghostwriters, polo shirts, and the fall of a landmark pesticide study
A flagship study that declared the weedkiller Roundup posed no serious health risks has been retracted with little fanfare, ending a 25-year saga that exposed how corporate interests can distort scientific research and influence government decision-making.
Published in Regulatory Toxicology and Pharmacology in 2000, the paper ranks in the top 0.1 percent of citations among studies on glyphosate -- the key ingredient in Roundup, owned by agri-giant Monsanto and at the center of cancer lawsuits worth billions of dollars.
In his retraction note last week, the journal's editor-in-chief, Martin van den Berg, cited a litany of serious flaws from failing to include carcinogenicity studies available at the time to undisclosed contributions by Monsanto employees and even questions around financial compensation.
Elsevier, the journal's Dutch publisher, told AFP in a statement that it upholds the "highest standards of rigor and ethics" and that "as soon as the current editor became aware of concerns regarding this paper a matter of months ago, due process began."
But it did not address the fact that concerns date back to 2002, when critics wrote to Elsevier about "conflicts of interest, lack of transparency, and the absence of editorial independence" at the journal, including specific worries about Monsanto.
The matter exploded into public view in 2017, when internal corporate documents released during litigation showed one of Monsanto's own scientists admitting to "ghostwriting."
Harvard University science historian Naomi Oreskes, who co-authored a paper this September detailing the extent of the "fraud" in the 2000 study, told AFP that while she was "very gratified" at the "long overdue" action, but warned that "the scientific community needs better mechanisms to identify and retract fraudulent papers."
"This is completely in alignment with what we were calling them out for at the time," Lynn Goldman, a pediatrician and epidemiologist at GWU who co-signed the 2002 letter, added to AFP.
- Polo shirts -
Two of the paper's three original authors have since died, while first author Gary Williams, a professor at New York Medical College, did not respond to AFP's request for comment.
Monsanto maintains it acted appropriately, and that its product is safe. "Monsanto's involvement with the Williams et al paper did not rise to the level of authorship and was appropriately disclosed in the acknowledgments."
The company declined to comment on internal emails that suggested otherwise, including one in which a Monsanto scientist asked a colleague whether "the team of people" who worked on the Williams paper and another study "could receive Roundup polo shorts as a token of appreciation for a job well done."
Glyphosate was brought to market as a herbicide in the 1970s and initially welcomed as less toxic than DDT.
But its soaring use -- especially after Monsanto introduced glyphosate-tolerant seeds that allowed it to be sprayed widely over crops -- drew increasing scrutiny in the 1990s, making the 2000 paper hugely influential.
According to Oreskes's research, it was cited as supporting evidence for glyphosate's safety by groups ranging from the Canadian Forest Service to the International Court of Justice, the US Congress and the European Parliamentary Research Service.
- Legal interest -
In 2015, the World Health Organization's International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans."
Several countries have since moved to restrict or ban its use, including France, which has prohibited household applications. Bayer, which acquired Monsanto, said it would phase out Roundup for US residential use in 2023 in response to growing lawsuits.
Nathan Donley, a scientist with the Center for Biological Diversity, told AFP he does not expect the retraction to sway the US Environmental Protection Agency, now under the pro-agricultural-industry Donald Trump administration, which has thrown its weight behind Bayer in an ongoing Supreme Court case.
But "it could play a role in litigation that is moving forward in the US against the EPA's proposed decision to renew glyphosate," Donley told AFP, adding that European regulators might also take note.
For Donley and others, the deeper concern is that the case may be far from unique.
"I am sure there (are a) lot (of) such ghost-written and undeclared conflict papers in the literature, but they are very difficult to unearth unless one goes really deep in litigation cases," John Ioannidis, a Stanford University professor who founded the field of meta-research told AFP.
M.Vogt--VB